Novo Nordisk resubmits higher-dosage Ozempic application to the FDA
After Novo Nordisk's previous FDA application was returned due to missing data, the firm has resubmitted a label expansion application for Ozempic on the world's largest market for diabetes products.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
On Friday, Novo Nordisk announced in a company statement that it has once again applied to the US Food and Drug Administration (FDA) for permission to start marketing the weekly diabetes treatment Ozempic in a higher dosage.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis increases expenses shortly before moment of truth
For subscribers
Novo Nordisk risks insulin shock on Chinese market
For subscribers
